← Russell 3000 cross-section

WHWK Whitehawk Therapeutics, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$283m
Revenue TTM
$0m
Net income TTM
$-80m
Free cash flow
$-69m
Composite score
34.2
Sector rank
#2697

Valuation

P / E
EV / EBITDA
EV / sales
FCF yield
-24.50%
Earnings yield vs 10-yr
-32.92pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
EBITDA margin
ROE
-43.6%
ROIC
Revenue growth
-100.0%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, effective April 1, 2013, which, due to subsequent legislative amendments, will stay in effect through 2032, unless additional congressional action is taken. The PIPL allows for fines of up to 50 million renminbi or 5% of a covered company’s revenue in the prior year.Whitehawk Therapeutics, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →